Compare Eli Lilly And Co (LLY) vs YieldMax Universe Fund of Option Income ETFs (YMAX) Price & Performance

Eli Lilly (LLY) trades at $1,150.86, down 2.39% on the day, with a bullish technical signal from moving averages and strong fundamental performance. The company reported robust earnings beats in recent quarters, with Q1 2026 EPS of $8.55 exceeding expectations by 23%. Revenue surged to $65.18 billion in 2025, driving a net income margin of 34.99%. Recent news highlights LLY's $2.8 billion acquisition of AtaiBeckley to expand its neuroscience pipeline, signaling strategic growth in mental health treatments.

Outlook remains positive with analyst consensus price target of $1,380 implying 20% upside, supported by 73% buy ratings. Key risks include high valuation multiples (P/E 41.89) and rising debt levels, though operating cash flow growth to $16.81 billion in 2025 provides financial flexibility. Investors should monitor Q2 2026 earnings on August 5 for continued execution on weight-loss drug demand and integration of recent acquisitions.

YMAX trades at $7.52 with no recent price movement. Technical indicators show a bearish trend, with moving averages signaling sell pressure and oscillators neutral. The fund generates weekly dividend income, though recent news highlights concerns over fee structures impacting payouts. Support and resistance are tightly clustered around $7 and $8, indicating limited near-term price range.

Outlook remains cautious due to bearish technicals and cost structure headwinds. The high-yield strategy offers income but faces erosion from layered fees. Key risks include dependency on market volatility for strategy success and competitive pressures in the ETF space. Investors should weigh yield against potential capital depreciation.